"Most people are more comfortable taking a pill than regularly injecting themselves, says Daniel Drucker, an endocrinologist at the University of Toronto, who previously consulted for Novo Nordisk. It's just good to have more options for people, he says. At the same time, the pills could greatly improve access to the medication by lowering coststhe injections can cost hundreds of dollars per month out of pocket."
"In the company's latest phase 3 clinical trial, the highest dose of the pill resulted in a 16.6 percent weight loss at 64 weeks compared with a 2.7 percent loss among those who took a placebo. For comparison, trials of 2.4 milligrams of Wegovy injections showed up to 17.4 percent weight reduction. (The injection and pill were not compared in a head-to-head trial.)"
"Weight-loss pills that harness the same mechanism as the wildly popular drugs Wegovy and Ozempic are coming to the U.S. On Monday Novo Nordisk announced that the U.S. Food and Drug Administration approved its oral glucagonlike peptide 1 (GLP-1) medication for weight loss and obesity in adults. It's a milestone for the industry, which has struggled to make effective pill versions of the weight-loss injections for years."
Novo Nordisk received U.S. Food and Drug Administration approval for an oral glucagonlike peptide 1 (GLP-1) medication for weight loss and obesity in adults. Many people prefer taking a pill to injecting medication, which could broaden treatment options and reduce barriers. Oral pills may lower out-of-pocket costs because injections can cost hundreds of dollars per month and are easier to transport and produce, potentially improving access. Phase 3 trial results showed the highest pill dose produced a 16.6 percent weight loss at 64 weeks versus 2.7 percent for placebo, while injectable Wegovy trials showed up to 17.4 percent reduction; no head-to-head comparison was conducted.
Read at www.scientificamerican.com
Unable to calculate read time
Collection
[
|
...
]